Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?

• Mahesh Swaminathan,
• Farhad Ravandi

Affiliations

Mahesh Swaminathan

The University of Texas, MD Anderson Cancer Center, Department of Leukemia, Texas

Farhad Ravandi

The University of Texas, MD Anderson Cancer Center, Department of Leukemia, Texas